Calcitriol (calcitriol)
Vitamin D Intravenous Ampul (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: Calcitriol is a man-made active form of vitamin D (vitamin D3). Vitamin D is a vitamin stored in the body that is needed for building and keeping strong bones. Calcitriol is used to treat or prevent certain problems that can happen with long-term kidney dialysis, such as low levels of calcium or high levels of parathyroid hormone.
Calcitriol is usually used along with a certain diet, supplements, and sometimes other medications. Most people get enough vitamin D from exposure to the sun and from fortified food products (such as dairy products, vitamins). Before regular vitamin D can be used by the body, it needs to be changed to the active form by the liver and kidneys.
People with kidney disease cannot make enough of the active form of vitamin D. This medication works by affecting parathyroid hormone (PTH) levels and increasing blood calcium levels.
Generic name: calcitriol
Pronunciation: (KAL-si-TRYE-ol)
Drug class: Vitamin D
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Calcitriol
Indications
The following indications are listed for Calcitriol:
- Hyperparathyroidism Secondary To Chronic Renal Failure
- Hypocalcemia
- Hypocalcemia From End-Stage Renal Disease With Dialysis
- Hypoparathyroidism
- Hypophosphatemia
- Renal Osteodystrophy
Also known as: Abnormally Decreased Blood Phosphate Level, Abnormally Decreased Serum Calcium, Condition Due To Low Levels Of Pth, Decreased Serum Calcium Due To Chronic Dialysis, Hyperparathyroidism Secondary To Crf, Hypocalcemia From End Stage Renal Disease With Dialysis, Hypocalcemia Secondary To Chronic Dialysis.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Oral Phosphates; Active Vitamin D Analogs/Burosumab
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Both burosumab and phosphates or vitamin D may increase serum phosphate levels. This combination may lead to greater increases in serum phosphate than anticipated.
CLINICAL EFFECTS: The combination of burosumab with oral phosphates or active vitamin D analogs may result in hyperphosphatemia and may increase the risk of nephrocalcinosis.(1)
PREDISPOSING FACTORS: Patients with renal impairment have alterations in mineral metabolism that may increase the risk of hyperphosphatemia.(1)
PATIENT MANAGEMENT: The concomitant use of burosumab with oral phosphates or active vitamin D analogs is contraindicated. Discontinue oral phosphate and/or active vitamin D analogs one week before starting burosumab.(1)
DISCUSSION: Burosumab restores dysfunctional renal phosphate reabsorption and renal production of 1,25-dihydroxyvitamin D to treat X-linked hypophosphatemia. Additional oral phosphates and/or active vitamin D analogs may raise serum phosphate higher than anticipated.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Serum Phosphate Level-Altering Drugs/Erdafitinib
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Medications that alter serum phosphate may interfere with interpretation of phosphate levels that are needed to determine initial erdafitinib dose.(1)
CLINICAL EFFECTS: Serum phosphate levels that are elevated by concomitant medications may result in an inappropriately low dose and decreased effectiveness of erdafitinib. Serum phosphate levels that are decreased by concomitant medications may result in an inappropriately high dose and increased toxicity from erdafitinib.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of erdafitinib states that agents that alter serum phosphate levels should be avoided before the initial dose increase period for erdafitinib based on serum phosphate levels (days 14 to 21).(1)
DISCUSSION: Concomitant administration of serum phosphate level-altering agents during the initial dose increase period of erdafitinib based on serum phosphate levels (days 14 to 21) may interfere with serum phospate levels and lead to incorrect dosing of erdafitinib.(1) Agents that may alter serum phosphate levels linked to this monograph include: aluminum carbonate, aluminum hydroxide, calcium acetate, calcium carbonate, calcium citrate, cod liver oil, ferric citrate, lanthanum, magnesium carbonate, magnesium hydroxide, potassium phosphate, sevelamer, sodium phosphate, sucroferric oxyhydroxide, tenapanor, and vitamin D.(1)
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Hypervitaminosis D
- Hypercalcemia
- Hyperphosphatemia
- Kidney stone
- Kidney disease with reduction in glomerular filtration rate (GFr)
- Sarcoidosis
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Abnormal hepatic function tests
- Acute pancreatitis
- Anaphylaxis
- Bone pain
- Cardiac arrhythmia
- Conjunctivitis
- Dehydration
- Drug-induced psychosis
- Erythema multiforme
- Fever
- Hypercalcemia
- Hypersensitivity drug reaction
- Hypertension
- Urinary tract infection
Rare or Very Rare
- Abdominal pain with cramps
- Anorexia
- Constipation
- Drowsy
- Dysgeusia
- General weakness
- Headache disorder
- Hypercholesterolemia
- Libido changes
- Myalgia
- Nausea
- Nocturia
- Photophobia
- Polydipsia
- Polyuria
- Proteinuria
- Pruritus of skin
- Rhinorrhea
- Vomiting
- Weight loss
- Xerostomia
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Hyperparathyroidism secondary to chronic renal failure | ||
| N25.81 | ICD10CM | Secondary hyperparathyroidism of renal origin |
| Hypocalcemia | ||
| E20.810 | ICD10CM | Autosomal dominant hypocalcemia |
| E83.51 | ICD10CM | Hypocalcemia |
| P71.0 | ICD10CM | Cow's milk hypocalcemia in newborn |
| P71.1 | ICD10CM | Other neonatal hypocalcemia |
| Hypocalcemia from end-stage renal disease with dialysis | ||
| E83.51 | ICD10CM | Hypocalcemia |
| Hypoparathyroidism | ||
| E20 | ICD10CM | Hypoparathyroidism |
| E20.0 | ICD10CM | Idiopathic hypoparathyroidism |
| E20.1 | ICD10CM | Pseudohypoparathyroidism |
| E20.8 | ICD10CM | Other hypoparathyroidism |
| E20.81 | ICD10CM | Hypoparathyroidism due to impaired parathyroid hormone secretion |
| E20.810 | ICD10CM | Autosomal dominant hypocalcemia |
| E20.811 | ICD10CM | Secondary hypoparathyroidism in diseases classified elsewhere |
| E20.812 | ICD10CM | Autoimmune hypoparathyroidism |
| E20.818 | ICD10CM | Other specified hypoparathyroidism due to impaired parathyroid hormone secretion |
| E20.819 | ICD10CM | Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified |
| E20.89 | ICD10CM | Other specified hypoparathyroidism |
| E20.9 | ICD10CM | Hypoparathyroidism, unspecified |
| E89.2 | ICD10CM | Postprocedural hypoparathyroidism |
| Hypophosphatemia | ||
| E83.31 | ICD10CM | Familial hypophosphatemia |
| Renal osteodystrophy | ||
| N25.0 | ICD10CM | Renal osteodystrophy |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.